Publications by authors named "A F LoBuglio"

Claim this Profile
T
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Christos Vaklavas, Brian S Roberts, Katherine E Varley, Nancy U Lin, Minetta C Liu, Albert F LoBuglio

Breast Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab-Resistant HER2 Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.
Monica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, Tiffiny S Cooper, Ling Zeng, Albert F LoBuglio

Mol Cancer Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.
Andres Forero, Yufeng Li, Dongquan Chen, William E Grizzle, Katherine L Updike, Albert F LoBuglio

Cancer Immunol Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
Jennifer Stanley, Lisa Klepczyk, Kimberly Keene, Shi Wei, Yufeng Li, Albert F LoBuglio

Breast Cancer Res Treat· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent read-through fusion transcripts in breast cancer.
Katherine E Varley, Jason Gertz, Brian S Roberts, Nicholas S Davis, Kevin M Bowling, Albert F LoBuglio

Breast Cancer Res Treat· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis